On the contrary, the higher expression of TMEM219 was better for survival in mesothelioma (FDR = 2.14E-3 (HR = 0.39)), lower grade glioma (FDR = 9.54E-3 (HR =0.54)), prostate adenocarcinoma (FDR = 2.02∙10−1 (HR = 0.18)), thyroid carcinoma (FDR = 1.332∙10−1 (HR = 0.39)) and bladder urothelial carcinoma (FDR = 9.54∙10−3 (HR = 0.61)) (Figure 7D–F). The gene discussed is TMEM219; the disease is central nervous system cancer.